Dimensional Fund Advisors
GNMX

Dimensional Fund Advisors’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Dimensional Fund Advisors’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,406
Closed -$19K – 3573
2014
Q2 		$19K Hold
2,406
– – ﹤0.01% 3502
2014
Q1 		$17K Hold
2,406
– – ﹤0.01% 3514
2013
Q4 		$14K Hold
2,406
– – ﹤0.01% 3486
2013
Q3 		$19K Buy
+2,406
New +$11.2K ﹤0.01% 3502

Other funds holding GNMX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors's GNMX Position: Q3 2014 in Review

Dimensional Fund Advisors sold out of Aevi Genomic Medicine Inc (GNMX) in Q3 2014, closing a stake of 2,406 shares — an estimated $19K sold.

Dimensional Fund Advisors first reported a position in GNMX in Q3 2013 and held it in 4 quarters. The position peaked at $19K in Q2 2014. 24 funds tracked by Wall St. Rank hold GNMX as of Q3 2014.

  • Dimensional Fund Advisors reported no remaining Aevi Genomic Medicine Inc position as of Q3 2014 after selling out during the quarter.
  • Dimensional Fund Advisors sold 2,406 Aevi Genomic Medicine Inc shares in Q3 2014, an estimated $19K.
  • Dimensional Fund Advisors first reported a position in Aevi Genomic Medicine Inc in Q3 2013 and held it in 4 quarters.
  • Dimensional Fund Advisors's Aevi Genomic Medicine Inc position peaked at $19K in Q2 2014.
  • 24 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2014.

Based on Dimensional Fund Advisors's 13F filing for Q3 2014, filed 13 Nov 2014.